G007-LK tankyrase 1/2 inhibitor: Precision Tool for Wnt/β-catenin and Cancer Biology

Executive Summary: G007-LK is a potent and selective tankyrase 1/2 inhibitor that suppresses Wnt/β-catenin signaling by inhibiting poly(ADP-ribosyl)ation with nanomolar efficacy in vitro (IC₅₀ = 46 nM for TNKS1, 25 nM for TNKS2) [APExBIO]. In APC-mutant colorectal cancer and Wnt3a-induced HEK 293 cells, it induces β-catenin degradation and stabilizes AXIN1/2, reducing cytosolic and nuclear β-catenin levels [Jia et al., 2017]. In vivo, G007-LK inhibits tumor growth in COLO-320DM xenograft mouse models, demonstrating translational relevance. The compound is insoluble in water and ethanol but highly soluble in DMSO (≥26.5 mg/mL), requiring careful workflow integration. G007-LK is validated for dissecting Wnt/β-catenin and Hippo pathway interactions, and its application boundaries are well-defined in recent literature.

Biological Rationale

Tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) are poly(ADP-ribose) polymerases crucial for the regulation of Wnt/β-catenin signaling and telomere maintenance [Jia et al., 2017]. Dysregulated tankyrase activity has been implicated in multiple malignancies, including hepatocellular carcinoma and APC-mutant colorectal cancer. Elevated tankyrase levels correlate with increased nuclear β-catenin and tumor cell proliferation. Targeted inhibition of tankyrases disrupts Wnt/β-catenin pathway signaling, leading to tumor growth suppression and induction of β-catenin degradation complexes. G007-LK, developed and supplied by APExBIO, is engineered for maximal selectivity toward TNKS1/2, providing a precise chemical tool for pathway deconvolution [APExBIO].

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK inhibits tankyrase 1 and tankyrase 2 by blocking their auto-poly(ADP-ribosyl)ation activity. This leads to stabilization of AXIN1/2, key scaffolding proteins in the β-catenin destruction complex. In Wnt/β-catenin-active cells, G007-LK administration results in reduced β-catenin levels through enhanced proteasomal degradation. In APC-mutant colorectal cancer cell lines (e.g., SW480), G007-LK induces the formation of "degradasomes" containing phosphorylated β-catenin, β-TrCP, and ubiquitin, facilitating complex assembly and β-catenin turnover [Jia et al., 2017]. In hepatocellular carcinoma models, tankyrase inhibition also upregulates Angiomotin-like 1/2 (AMOTL1/2), which further inhibits YAP nuclear translocation, linking Wnt and Hippo pathway suppression. The result is a dual blockade of oncogenic transcriptional programs.

Evidence & Benchmarks

• G007-LK inhibits TNKS1 and TNKS2 auto-poly(ADP-ribosyl)ation with IC₅₀ values of 46 nM and 25 nM, respectively, under standard in vitro enzyme assay conditions (APExBIO, product page).
• In Wnt3a-induced HEK 293 cells, G007-LK suppresses Wnt signaling reporter ST-Luc with an IC₅₀ of 0.05 μM (APExBIO, product page).
• In APC-mutant colorectal cancer cell lines (SW480), G007-LK induces formation of β-catenin degradasomes and reduces cytosolic/nuclear β-catenin (Jia et al., 2017, DOI).
• In COLO-320DM xenograft mouse models, G007-LK reduces tumor volume and protein levels of TNKS1/2 and β-catenin, while stabilizing AXIN1/2 (APExBIO, product page).
• In HCC cell lines, G007-LK synergizes with MEK and AKT inhibitors to further suppress proliferation (Jia et al., 2017, DOI).
• Tankyrase inhibitors including G007-LK decrease YAP protein levels and YAP/TEAD transcriptional activity, upregulating AMOTL1/2 (Jia et al., 2017, DOI).

This article extends the mechanistic depth of "G007-LK: Precision Tankyrase 1/2 Inhibition for APC-Mutant Cancer" by integrating recent in vivo and Hippo pathway data.

It also clarifies workflow parameters and solubility constraints not fully discussed in "G007-LK: Specific Tankyrase 1/2 Inhibitor for Wnt and Cancer Research".

For a translational perspective, see "G007-LK Tankyrase 1/2 Inhibitor: Catalyzing Translational Discovery"; this article updates limits and workflow for preclinical deployment.

Applications, Limits & Misconceptions

G007-LK is primarily used for dissecting Wnt/β-catenin signaling in APC-mutant colorectal cancer, hepatocellular carcinoma, and related malignancies. It is suitable for in vitro, cellular, and xenograft studies where precise suppression of tankyrase activity is required. The compound is not recommended for use in water- or ethanol-based assays due to insolubility. Long-term storage of DMSO solutions can lead to degradation; short-term solid storage at -20°C is optimal. G007-LK is not a pan-PARP inhibitor and does not broadly inhibit other PARP family members. Its effects on non-tankyrase pathways are indirect and context-dependent.

Common Pitfalls or Misconceptions

• Assuming G007-LK is a general PARP inhibitor—its selectivity is restricted to tankyrase 1/2 and does not broadly inhibit other PARPs.
• Using water or ethanol as solvents—G007-LK is insoluble in these and must be dissolved in DMSO (≥26.5 mg/mL).
• Expecting efficacy in non-Wnt/β-catenin-driven tumors—efficacy is highest in cancers dependent on tankyrase-mediated Wnt signaling.
• Long-term storage of solutions—DMSO stock solutions degrade over time; keep solid at -20°C and prepare fresh solutions as needed.
• Interpreting YAP inhibition as direct—G007-LK downregulates YAP via stabilization of AMOTL1/2, not by direct YAP inhibition.

Workflow Integration & Parameters

To prepare G007-LK for biological assays, dissolve the solid in DMSO at concentrations up to or exceeding 26.5 mg/mL. For optimal solubility, warm at 37°C or use ultrasonic bath treatment. Avoid water or ethanol as solvents. Store solid compound at -20°C. Prepare aliquots to minimize freeze-thaw cycles. In cell-based assays, typical working concentrations range from 10 nM to 1 μM, depending on the system and endpoint. In vivo dosing regimens should be modeled on published xenograft protocols [APExBIO]. Monitor β-catenin, AXIN1/2, and YAP target gene expression as pharmacodynamic markers.

Conclusion & Outlook

G007-LK tankyrase 1/2 inhibitor (B5830) is a validated, highly selective tool for Wnt/β-catenin and Hippo pathway research with proven efficacy in APC mutation colorectal cancer and hepatocellular carcinoma models. Its robust benchmarks, well-defined workflow parameters, and translational relevance make it indispensable for cancer biology researchers. Future work may explore combination regimens and further dissect indirect pathway interactions. For product specifications and ordering, visit the APExBIO G007-LK tankyrase 1/2 inhibitor page.